36045450|t|Differential impairment of cerebrospinal fluid synaptic biomarkers in the genetic forms of frontotemporal dementia.
36045450|a|BACKGROUND: Approximately a third of frontotemporal dementia (FTD) is genetic with mutations in three genes accounting for most of the inheritance: C9orf72, GRN, and MAPT. Impaired synaptic health is a common mechanism in all three genetic variants, so developing fluid biomarkers of this process could be useful as a readout of cellular dysfunction within therapeutic trials. METHODS: A total of 193 cerebrospinal fluid (CSF) samples from the GENetic FTD Initiative including 77 presymptomatic (31 C9orf72, 23 GRN, 23 MAPT) and 55 symptomatic (26 C9orf72, 17 GRN, 12 MAPT) mutation carriers as well as 61 mutation-negative controls were measured using a microflow LC PRM-MS set-up targeting 15 synaptic proteins: AP-2 complex subunit beta, complexin-2, beta-synuclein, gamma-synuclein, 14-3-3 proteins (eta, epsilon, zeta/delta), neurogranin, Rab GDP dissociation inhibitor alpha (Rab GDI alpha), syntaxin-1B, syntaxin-7, phosphatidylethanolamine-binding protein 1 (PEBP-1), neuronal pentraxin receptor (NPTXR), neuronal pentraxin 1 (NPTX1), and neuronal pentraxin 2 (NPTX2). Mutation carrier groups were compared to each other and to controls using a bootstrapped linear regression model, adjusting for age and sex. RESULTS: CSF levels of eight proteins were increased only in symptomatic MAPT mutation carriers (compared with controls) and not in symptomatic C9orf72 or GRN mutation carriers: beta-synuclein, gamma-synuclein, 14-3-3-eta, neurogranin, Rab GDI alpha, syntaxin-1B, syntaxin-7, and PEBP-1, with three other proteins increased in MAPT mutation carriers compared with the other genetic groups (AP-2 complex subunit beta, complexin-2, and 14-3-3 zeta/delta). In contrast, CSF NPTX1 and NPTX2 levels were affected in all three genetic groups (decreased compared with controls), with NPTXR concentrations being affected in C9orf72 and GRN mutation carriers only (decreased compared with controls). No changes were seen in the CSF levels of these proteins in presymptomatic mutation carriers. Concentrations of the neuronal pentraxins were correlated with brain volumes in the presymptomatic period for the C9orf72 and GRN groups, suggesting that they become abnormal in proximity to symptom onset. CONCLUSIONS: Differential synaptic impairment is seen in the genetic forms of FTD, with abnormalities in multiple measures in those with MAPT mutations, but only changes in neuronal pentraxins within the GRN and C9orf72 mutation groups. Such markers may be useful in future trials as measures of synaptic dysfunction, but further work is needed to understand how these markers change throughout the course of the disease.
36045450	91	114	frontotemporal dementia	Disease	MESH:D057180
36045450	153	176	frontotemporal dementia	Disease	MESH:D057180
36045450	178	181	FTD	Disease	MESH:D057180
36045450	264	271	C9orf72	Gene	203228
36045450	273	276	GRN	Gene	2896
36045450	282	286	MAPT	Gene	4137
36045450	568	571	FTD	Disease	MESH:D057180
36045450	615	622	C9orf72	Gene	203228
36045450	627	630	GRN	Gene	2896
36045450	635	639	MAPT	Gene	4137
36045450	664	671	C9orf72	Gene	203228
36045450	676	679	GRN	Gene	2896
36045450	684	688	MAPT	Gene	4137
36045450	830	855	AP-2 complex subunit beta	Gene	163
36045450	857	868	complexin-2	Gene	10814
36045450	870	884	beta-synuclein	Gene	6620
36045450	886	901	gamma-synuclein	Gene	6623
36045450	903	945	14-3-3 proteins (eta, epsilon, zeta/delta)	Gene	7533;7531
36045450	947	958	neurogranin	Gene	4900
36045450	960	996	Rab GDP dissociation inhibitor alpha	Gene	2664
36045450	998	1011	Rab GDI alpha	Gene	2664
36045450	1014	1025	syntaxin-1B	Gene	112755
36045450	1027	1037	syntaxin-7	Gene	8417
36045450	1039	1081	phosphatidylethanolamine-binding protein 1	Gene	5037
36045450	1083	1089	PEBP-1	Gene	5037
36045450	1092	1119	neuronal pentraxin receptor	Gene	23467
36045450	1121	1126	NPTXR	Gene	23467
36045450	1129	1149	neuronal pentraxin 1	Gene	4884
36045450	1151	1156	NPTX1	Gene	4884
36045450	1163	1183	neuronal pentraxin 2	Gene	4885
36045450	1185	1190	NPTX2	Gene	4885
36045450	1407	1411	MAPT	Gene	4137
36045450	1478	1485	C9orf72	Gene	203228
36045450	1489	1492	GRN	Gene	2896
36045450	1512	1526	beta-synuclein	Gene	6620
36045450	1528	1543	gamma-synuclein	Gene	6623
36045450	1545	1555	14-3-3-eta	Gene	7533
36045450	1557	1568	neurogranin	Gene	4900
36045450	1570	1583	Rab GDI alpha	Gene	2664
36045450	1585	1596	syntaxin-1B	Gene	112755
36045450	1598	1608	syntaxin-7	Gene	8417
36045450	1614	1620	PEBP-1	Gene	5037
36045450	1661	1665	MAPT	Gene	4137
36045450	1724	1749	AP-2 complex subunit beta	Gene	163
36045450	1751	1762	complexin-2	Gene	10814
36045450	1768	1785	14-3-3 zeta/delta	Gene	7534
36045450	1805	1810	NPTX1	Gene	4884
36045450	1815	1820	NPTX2	Gene	4885
36045450	1911	1916	NPTXR	Gene	23467
36045450	1950	1957	C9orf72	Gene	203228
36045450	1962	1965	GRN	Gene	2896
36045450	2233	2240	C9orf72	Gene	203228
36045450	2245	2248	GRN	Gene	2896
36045450	2351	2370	synaptic impairment	Disease	MESH:D012183
36045450	2403	2406	FTD	Disease	MESH:D057180
36045450	2462	2466	MAPT	Gene	4137
36045450	2529	2532	GRN	Gene	2896
36045450	2537	2544	C9orf72	Gene	203228
36045450	2621	2641	synaptic dysfunction	Disease	MESH:C536122
36045450	Association	4137	4900
36045450	Association	163	4137
36045450	Association	4137	7534
36045450	Positive_Correlation	4137	6623
36045450	Association	MESH:D057180	203228
36045450	Association	MESH:D057180	2896
36045450	Positive_Correlation	4137	6620
36045450	Association	MESH:D057180	4137
36045450	Association	10814	4137
36045450	Positive_Correlation	4137	8417
36045450	Positive_Correlation	2664	4137
36045450	Positive_Correlation	112755	4137
36045450	Positive_Correlation	4137	5037

